Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To determine the motor-behavioral and neural correlates of putative functional common variants in the sodium-channel NaV1.8 encoding gene (SCN10A) in vivo in patients with multiple sclerosis (MS).
Methods: We recruited 161 patients with relapsing-onset MS and 94 demographically comparable healthy participants. All patients with MS underwent structural MRI and clinical examinations (Expanded Disability Status Scale [EDSS] and Multiple Sclerosis Functional Composite [MSFC]). Whole-brain voxel-wise and cerebellar volumetry were performed to assess differences in regional brain volumes between genotype groups. Resting-state fMRI was acquired from 62 patients with MS to evaluate differences in cerebellar functional connectivity. All participants were genotyped for 4 potentially functional SCN10A polymorphisms.
Results: Two SCN10A polymorphisms in high linkage disequilibrium (r2 = 0.95) showed significant association with MSFC performance in patients with MS (rs6795970: p = 6.2 × 10−4; rs6801957: p = 0.0025). Patients with MS with rs6795970AA genotype performed significantly worse than rs6795970G carriers in MSFC (p = 1.8 × 10−4) and all of its subscores. This association was independent of EDSS and cerebellar atrophy. Although the genotype groups showed no difference in regional brain volumes, rs6795970AA carriers demonstrated significantly diminished cerebellar functional connectivity with the thalami and midbrain. No significant SCN10A–genotype effect was observed on MSFC performance in healthy participants.
Conclusions: Our data suggest that SCN10A variation substantially influences functional status, including prominent effects on motor coordination in patients with MS. These findings were supported by the effects of this variant on a neural system important for motor coordination, namely cerebello-thalamic circuitry. Overall, our findings add to the emerging evidence that suggests that sodium channel NaV1.8 could serve as a target for future drug-based interventions to treat cerebellar dysfunction in MS.
GLOSSARY
- BOLD=
- blood oxygenation level–dependent;
- CRIMSON=
- Cross-Modal Research Initiative for Multiple Sclerosis and Optic Neuritis;
- EAE=
- experimental autoimmune encephalomyelitis;
- EDSS=
- Expanded Disability Status Scale;
- FWE=
- familywise error;
- MAF=
- minor allele frequency;
- MS=
- multiple sclerosis;
- MSFC=
- Multiple Sclerosis Functional Composite;
- PASAT=
- Paced Auditory Serial Addition Test;
- ROI=
- region of interest;
- SARA=
- Scale for the Assessment and Rating of Ataxia;
- SNP=
- single nucleotide polymorphism
Footnotes
↵* These authors contributed equally to this work.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
Editorial, page 406
See page 473
- Received December 26, 2014.
- Accepted in final form July 27, 2015.
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
The Multiple Sclerosis Functional CompositeA clinically meaningful measure of disabilityChris H. Polman, Richard A. Rudick et al.Neurology, April 26, 2010 -
Article
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGavin Giovannoni, Jeffrey A. Cohen, Alasdair J. Coles et al.Neurology, October 12, 2016 -
Articles
Comparisons of patient self-report, neurologic examination, and functional impairment in MSE.L.J. Hoogervorst, L.M.L. van Winsen, M.J. Eikelenboom et al.Neurology, April 10, 2001 -
Article
Network Damage Predicts Clinical Worsening in Multiple SclerosisA 6.4-Year StudyMaria A. Rocca, Paola Valsasina, Alessandro Meani et al.Neurology: Neuroimmunology & Neuroinflammation, May 21, 2021